Semaglutide News and Research

Latest Semaglutide News and Research

Epigenetic changes favor development of fatty liver in humans and mice

Mice with a strong tendency to obesity already exhibit epigenetic changes at six weeks of age, inducing the liver to amplify its production of the enzyme DPP4 and release it into the circulation. Over the long term, this favors the development of a fatty liver.

9 Jan 2017

Platypus venom shows potential for new diabetes treatments

Australian researchers have discovered remarkable evolutionary changes to insulin regulation in two of the nation's most iconic native animal species - the platypus and the echidna - which could pave the way for new treatments for type 2 diabetes in humans.

29 Nov 2016

Results of high-impact clinical trials could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL.

21 Nov 2016

Medovex successfully conducts live tissue test of DenerveX System

Medovex Corp., a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX System under the most stringent standards required by FDA and other regulatory agencies.

4 Nov 2016

METTLER TOLEDO releases new weighing guide to optimize lab performance

In the highly competitive pharmaceutical industry, there is intense focus on laboratory efficiency. However, there are also stringent regulations to adhere to.

From Mettler-Toledo International Inc. 2 Nov 2016

Esperite's business unit develops therapy for Crohn's disease perianal fistulas

Esperite's business unit The Cell Factory in collaboration with Women's and Children's Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).

21 Oct 2016

OGT announces expansion of Cytocell Aquarius Haematology FISH probe range

Oxford Gene Technology, The Molecular Genetics Company, has today announced a significant expansion of its existing catalogue of Cytocell Aquarius Haematology probes for fluorescence in situ hybridisation (FISH) — underlining the company's position as the one-stop-shop for high-quality FISH probes.

13 Oct 2016

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.

8 Sep 2016

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

A combination of three medications—dapagliflozin, liraglutide and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Aug 2016

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

In an attempt to correct defects in the energy generation that contribute to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure.

2 Aug 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulin

When Amy Sweat was 19 years old, while she was in the hospital recovering from surgery, she was diagnosed with Type 2 diabetes. Ms. Sweat was treated for her diabetes, first on oral drugs, then on increasingly larger doses of insulin, but the years went by and she never was able to achieve good blood sugar control.

6 Jul 2016

Appetite hormone CART helps increase insulin secretion, reduce glucagon production

The study shows that the appetite hormone CART not only controls the sensation of satiety, but it also helps increase insulin secretion and decrease glucagon production.

30 Jun 2016

Empagliflozin offers long-term renal protection in Type 2 diabetes

The sodium-glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of the EMPA-REG OUTCOME trial.

16 Jun 2016

Liraglutide cardioprotective in high-risk Type 2 diabetes patients

Findings of the LEADER trial show that liraglutide treatment may confer a reduced risk of cardiovascular events in patients with Type 2 diabetes and a high vascular risk.

15 Jun 2016

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Researchers have shown that the glucose-lowering drug liraglutide safely and effectively decreases the overall risk of heart attack, stroke, or cardiovascular death for people with type 2 diabetes.

14 Jun 2016

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.

12 Jun 2016

New technique could help reduce chances of drug failure during later stages of clinical trials

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline.

2 Jun 2016

PYY hormone may offer effective treatment for type 2 diabetes

Researchers at the Norwegian University of Science and Technology and Oxford University have found a hormone that may offer an effective treatment for type 2 diabetes.

20 May 2016

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

Semaglutide News and Research

Latest Semaglutide News and Research

Epigenetic changes favor development of fatty liver in humans and mice

Platypus venom shows potential for new diabetes treatments

Results of high-impact clinical trials could improve kidney-related medical care

Medovex successfully conducts live tissue test of DenerveX System

METTLER TOLEDO releases new weighing guide to optimize lab performance

Esperite's business unit develops therapy for Crohn's disease perianal fistulas

OGT announces expansion of Cytocell Aquarius Haematology FISH probe range

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulin

Appetite hormone CART helps increase insulin secretion, reduce glucagon production

Empagliflozin offers long-term renal protection in Type 2 diabetes

Liraglutide cardioprotective in high-risk Type 2 diabetes patients

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

New technique could help reduce chances of drug failure during later stages of clinical trials

PYY hormone may offer effective treatment for type 2 diabetes

Clinical study shows sitagliptin drug not effective in treating NAFLD

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Semaglutide News and Research

Latest Semaglutide News and Research

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in